

To NASDAQ OMX Copenhagen A/S

Translation

Company release No 1/2009

Hørsholm
January 22, 2009

ALK acquires shares in DBV Technologies, France

Page 1/2

Summary: ALK invests in development of a peanut allergy vaccine

ALK has signed an agreement to invest EUR 2 million in the French biotech company DBV Technologies as part of a follow-up equity financing of the company.

The investment in DBV Technologies provides an opportunity for ALK to enter a collaboration on developing a new promising vaccine against peanut allergy. The peanut allergy vaccine, which is currently being developed by DBV Technologies, is based on a proprietary electro charged patch technology offering gradual uptake of the active vaccine ingredients through the skin.

Peanut allergy is one of the most severe food allergies. Peanut allergic patients may experience severe allergic reactions or even anaphylaxis when accidentally exposed to peanut allergens.

Currently, there are no allergy vaccine products or proven technologies available for the treatment of patients suffering from peanut allergy. As a result, patients rely on strict avoidance of peanuts combined with adrenaline auto-injectors for self-administration in case of an allergic emergency.

As part of the agreement, President and CEO Jens Bager will join DBV Technologies' Board of Directors. In accordance with its accounting policies, ALK will record the investment on the balance sheet under long-term financial assets.

ALK-Abelló A/S

Jens Bager
President & CEO

Contact person:

Jens Bager, President and CEO, tel. +45 4574 7576

About DBV Technologies

DBV Technologies (DBV) is a French biopharmaceutical company engaged in the development of non-invasive epicutaneous delivery technology and products. DBV Technologies is a private limited company, founded in 2002. DBV Technologies is lead by CEO Jean-François BIRY and was born on the experience of paediatricians Doctor Pierre-Henri Benhamou and Arts et Métiers institute engineer Bertrand Dupont. In 2003, DBV Technologies expanded with investment from venture capitalist groups Cap Décisif and Créagro. This funding was increased with Sofinnova Partners and Apax Partners investing further EUR 12.3 million in DBV Technologies in January 2006. DBV has 16 employees (2008).

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. Our mission is to improve quality of life for allergic people by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. Our aim is to extend the use of allergy vaccination by introducing new convenient vaccines, thereby offering many more patients a causal allergy treatment. Following this strategy, the world's first tablet-based vaccine against grass pollen allergy, GRAZAX[®], was launched in Europe in 2007, and ALK has entered into a strategic partnership with Schering-Plough in North America. ALK has approximately 1,500 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological Laboratory Copenhagen (København)'. Further information is available at www.alk-abello.com and www.GRAZAX.com.

For further information please contact:

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551